(Q37016582)

English

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

scientific article published on February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

ChEBI release 2020-05-28

gastrointestinal stromal tumor

1 reference

based on heuristic

inferred from title

author name string

G S Falchook

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

J C Trent

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

M C Heinrich

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

C Beadling

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

J Patterson

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

C C Bastida

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

S C Blackman

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

R Kurzrock

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

1 February 2013

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

310-315

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Predicting the functional impact of protein mutations: application to cancer genomics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

A method and server for predicting damaging missense mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

29 September 2017

BRAF mutation status in gastrointestinal stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

27 June 2018

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

27 June 2018

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

4 September 2018

Molecular Analysis of c-KitandPDGFRAin GISTs Diagnosed by EUS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3712576

4 December 2018

Mutations in gastrointestinal stromal tumors--a population-based study from Northern Norway

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.864

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37016582&oldid=2105666617"